Omni Bio Pharmaceutical, Inc. (“Omni Bio”), an emerging biopharmaceutical company formed to acquire, license, and develop existing therapies for indications with substantial commercialization potential, has committed to expand its Phase I/II human clinical trial in recently diagnosed Type 1 diabetes patients from 15 patients to 50…
Diabetes News From Medical News Today

March 1st, 2011
admin
Posted in
Tags: